Metachromatic leukodystrophy: Advancing therapies and navigating clinical frontiers

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board.

Author: Joaquin A Pena MD

Introduction

Metachromatic leukodystrophy is a severe, inherited neurodegenerative lysosomal storage disorder caused by deficient arylsulfatase A (ARSA) enzyme activity, leading to sulfatide accumulation in the CNS and PNS. This progressive accumulation results in profound motor and cognitive decline, often proving fatal. Metachromatic leukodystrophy subtypes are classified by age of symptom onset: late-infantile (LI, younger than 2.5 years), early-juvenile (EJ, 2.5 to 6 years), late-juvenile (LJ, 7 to 16 years), and adult (16 years or older). The presenting symptoms, particularly motor involvement, can significantly dictate disease course, with motor-predominant cases typically showing more rapid progression. Although individually rare (1 in 40,000 to 160,000), metachromatic leukodystrophy’s devastating impact necessitates effective interventions.

Current therapeutic approaches

The treatment landscape for metachromatic leukodystrophy is evolving beyond supportive care, with gene therapies at the forefront.

Allogeneic hematopoietic stem cell transplantation. Hematopoietic stem cell transplantation works by introducing donor-derived hematopoietic stem cells that differentiate into enzyme-producing microglia in the brain.

Efficacy and limitations. Hematopoietic stem cell transplantation offers significant benefit when performed pre-symptomatically for juvenile and adult metachromatic leukodystrophy, leading to stabilization of cognitive and motor function. However, its impact on late-infantile metachromatic leukodystrophy is limited, only delaying the inevitable severe motor dysfunction and death. A critical limitation is its poor efficacy on peripheral neuropathy, which often continues to progress. Hematopoietic stem cell transplantation carries substantial risks, including high mortality and morbidity from complications like graft-versus-host disease, infections, and organ damage. Donor availability is also a factor.

Lentiviral hematopoietic stem cell gene therapy (atidarsagene autotemcel/Lenmeldy™/Skysona™). This advanced therapy involves ex vivo genetic modification of a patient's hematopoietic stem cells with a lentiviral vector to express ARSA, followed by reinfusion after myeloablative conditioning.

Recent breakthroughs. Hematopoietic stem cell gene therapy has received regulatory approval in the EU, UK, and the US for the treatment of pre-symptomatic or early-symptomatic early-onset metachromatic leukodystrophy. Long-term studies confirm sustained, clinically relevant benefits in early-onset metachromatic leukodystrophy, demonstrating preserved cognitive and motor function, as well as delayed demyelination and brain atrophy, particularly when administered before symptom onset. This therapy achieves supraphysiological ARSA levels. A pilot study also suggests potential for postsymptomatic juvenile metachromatic leukodystrophy, showing disease stabilization.

Safety profile. Hematopoietic stem cell gene therapy is generally well tolerated, with no treatment-related deaths reported in initial trials. Adverse events are primarily associated with the conditioning regimen. Concerns about insertional mutagenesis exist; however, the current benefits for metachromatic leukodystrophy patients without matched donors typically outweigh these risks. Newer vector designs aim to enhance safety with reduced viral integration.

Other approaches.

In vivo gene therapy. In vivo gene therapy (rAAV vectors) for metachromatic leukodystrophy, which directly delivers genes to the brain, has shown promise in preclinical models but has had limited success in human trials, with some patients experiencing worsened disease progression and focal lesions, possibly due to leakage of the extracellular enzyme. Research into improved AAV capsids continues.

Enzyme replacement therapy. Enzyme replacement therapy, administered both intravenously and intrathecally, has faced challenges. Intravenous rhASA failed to cross the blood-brain barrier in therapeutic quantities. At the same time, intravenous rhASA, despite direct CNS delivery, did not demonstrate significant clinical benefit in halting motor decline and has been discontinued.

Impactful breakthrough: newborn screening

The emergence of newborn screening for metachromatic leukodystrophy is a transformative development.

Significance. Newborn screening enables early, presymptomatic identification, which is paramount for successful gene therapy outcomes. Metachromatic leukodystrophy meets the criteria for newborn screening programs.

Advancements. Feasibility studies using dried blood spots are successful, with recent methods improving accuracy by measuring specific sulfatide species to reduce false positives.

Clinical considerations. Newborn screening introduces complex ethical dilemmas regarding the diagnosis of late-onset metachromatic leukodystrophy or variants with uncertain prognoses, necessitating robust genetic counseling and support for families.

Unresolved debates and clinical challenges

Symptomatic treatment gap. A significant challenge remains for patients diagnosed at advanced symptomatic stages, where current approved therapies show limited benefit.

Peripheral nervous system involvement. The persistent challenge of effectively treating peripheral neuropathy across various therapies impacts long-term patient quality of life.

Prognostic uncertainty. Accurately predicting disease course for novel ARSA variants or pseudodeficiency alleles remains complex, impacting treatment decisions and family counseling.

Accessibility and cost. The extremely high cost of advanced gene therapies (millions of dollars per treatment) presents significant global challenges for equitable patient access.

Future directions and research gaps

Broadening therapeutic eligibility. Further research is crucial to determine if hematopoietic stem cell gene therapy can effectively treat a broader spectrum of symptomatic or patients with late-onset metachromatic leukodystrophy. Trials for late-juvenile metachromatic leukodystrophy (NCT04283227) are ongoing.

Optimizing gene vectors. The development of more efficient and safer lentiviral vectors (eg, EA1) and advancements in CRISPR/base-editing technologies hold promise for improved efficacy and reduced risks.

Novel biomarkers. Identifying and validating superior prognostic and predictive biomarkers is crucial for more accurate disease staging, predicting treatment response, and guiding early intervention in newborn screening-identified cases with uncertain phenotypes.

Long-term data and collaboration. The continuous collection of long-term safety and efficacy data, particularly from real-world cohorts and populations identified by newborn screening, is vital. Fostering international collaboration and multidisciplinary expert panels will be key to developing standardized guidelines and improving global access to specialized care.

The rapid evolution of metachromatic leukodystrophy therapies holds immense promise, particularly for early-onset forms of the disease. As clinicians, our continued engagement with emerging research and collaborative efforts is paramount to addressing persistent challenges and ensuring optimal, accessible care for all affected individuals.

References

Armstrong N, Olaye A, Noake C, and Pang F. A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel. Orphanet J Rare Dis 2023; 18:248. PMID 37644601

Asbreuk M, Schoenmakers D, Adang L, et al. Metachromatic Leukodystrophy. New Therapy Advancements and Emerging Research Directions. Neurology 2025;105:e213817. PMID 40577679

Chiao Chang S, Eichinger C, Field P. The natural history and burden of illness of metachromatic leukodystrophy: a systematic literature review. Eur J Med Res 2024; 29:181. PMID 38494502

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.